Specifically, findings from large cohort breast cancer clinical samples indicated that decreased MTSS1 expression was positively associated with poorer prognosis, whereas high levels of MTSS1 correlated with an increased overall patient survival [10]. This evidence concerns the gene MTSS1 and breast carcinoma.